Tags

Type your tag names separated by a space and hit enter

Risk of infections in patients treated with ticagrelor versus clopidogrel: a systematic review and meta-analysis.
Eur Heart J Cardiovasc Pharmacother. 2020 Jun 22 [Online ahead of print]EH

Abstract

AIMS

Ticagrelor has been shown to reduce the risk of pneumonia and improve lung function, but the findings across studies were inconsistent. The objective is to investigate the relative safety of ticagrelor versus clopidogrel on infection outcomes in patients with cardiovascular diseases.

METHODS AND RESULTS

We searched MEDLINE, EMBASE, Cochrane Library, and ClinicalTrials.gov up to 15 October 2019. Randomized controlled trials comparing ticagrelor and clopidogrel that reported infection outcomes were included. The primary outcome was pneumonia. Secondary outcomes were upper respiratory tract infection (URTI), urinary tract infection (UTI) and sepsis. Study quality was assessed using the Cochrane Risk of Bias tool. Study selection, data extraction and quality assessment were conducted by independent authors. Random-effects model was used for data synthesis. Relative risks (RRs) and 95% confidence intervals (CIs) were pooled with a random-effects model. Out of 5231 citations, ten trials with altogether 37514 patients were included. Ticagrelor was associated with a lower risk of pneumonia (RR 0.80, 95% CI 0.67 to 0.95) compared to clopidogrel. There were no statistically significant differences for URTI (RR 0.71, 95% CI 0.34 to 1.48), UTI (RR 1.06, 95% CI 0.73 to 1.64), or sepsis (RR 0.79, 95% CI 0.50 to 1.26).

CONCLUSIONS

Compared to clopidogrel, ticagrelor reduces the risk of pneumonia, but not URTI, UTI or sepsis. Our study provides further evidence for recommending ticagrelor to patients with acute coronary syndrome at risk of pneumonia, although the mechanism by which ticagrelor reduces the risk of pneumonia merits further research.

Authors+Show Affiliations

Division of Clinical Pharmacology and Therapeutics, Department of Medicine, LKS Faculty of Medicine, the University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong, China.Division of Clinical Pharmacology and Therapeutics, Department of Medicine, LKS Faculty of Medicine, the University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong, China.Division of Clinical Pharmacology and Therapeutics, Department of Medicine, LKS Faculty of Medicine, the University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong, China.Division of Clinical Pharmacology and Therapeutics, Department of Medicine, LKS Faculty of Medicine, the University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong, China.Division of Clinical Pharmacology and Therapeutics, Department of Medicine, LKS Faculty of Medicine, the University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong, China. State Key Laboratory of Pharmaceutical Biotechnology, the University of Hong Kong, Pokfulam, Hong Kong, China. Institute of Cardiovascular Science and Medicine, the University of Hong Kong, Pokfulam, Hong Kong, China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32569384

Citation

Long, Hang, et al. "Risk of Infections in Patients Treated With Ticagrelor Versus Clopidogrel: a Systematic Review and Meta-analysis." European Heart Journal. Cardiovascular Pharmacotherapy, 2020.
Long H, Feng Q, Tsoi MF, et al. Risk of infections in patients treated with ticagrelor versus clopidogrel: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2020.
Long, H., Feng, Q., Tsoi, M. F., Fei, Y., & Cheung, B. M. Y. (2020). Risk of infections in patients treated with ticagrelor versus clopidogrel: a systematic review and meta-analysis. European Heart Journal. Cardiovascular Pharmacotherapy. https://doi.org/10.1093/ehjcvp/pvaa065
Long H, et al. Risk of Infections in Patients Treated With Ticagrelor Versus Clopidogrel: a Systematic Review and Meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2020 Jun 22; PubMed PMID: 32569384.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Risk of infections in patients treated with ticagrelor versus clopidogrel: a systematic review and meta-analysis. AU - Long,Hang, AU - Feng,Qi, AU - Tsoi,Man Fung, AU - Fei,Yue, AU - Cheung,Bernard M Y, Y1 - 2020/06/22/ PY - 2020/02/25/received PY - 2020/05/20/revised PY - 2020/06/07/accepted PY - 2020/6/23/entrez PY - 2020/6/23/pubmed PY - 2020/6/23/medline KW - Clopidogrel KW - Infections KW - Meta-analysis KW - Pneumonia KW - Ticagrelor JF - European heart journal. Cardiovascular pharmacotherapy JO - Eur Heart J Cardiovasc Pharmacother N2 - AIMS: Ticagrelor has been shown to reduce the risk of pneumonia and improve lung function, but the findings across studies were inconsistent. The objective is to investigate the relative safety of ticagrelor versus clopidogrel on infection outcomes in patients with cardiovascular diseases. METHODS AND RESULTS: We searched MEDLINE, EMBASE, Cochrane Library, and ClinicalTrials.gov up to 15 October 2019. Randomized controlled trials comparing ticagrelor and clopidogrel that reported infection outcomes were included. The primary outcome was pneumonia. Secondary outcomes were upper respiratory tract infection (URTI), urinary tract infection (UTI) and sepsis. Study quality was assessed using the Cochrane Risk of Bias tool. Study selection, data extraction and quality assessment were conducted by independent authors. Random-effects model was used for data synthesis. Relative risks (RRs) and 95% confidence intervals (CIs) were pooled with a random-effects model. Out of 5231 citations, ten trials with altogether 37514 patients were included. Ticagrelor was associated with a lower risk of pneumonia (RR 0.80, 95% CI 0.67 to 0.95) compared to clopidogrel. There were no statistically significant differences for URTI (RR 0.71, 95% CI 0.34 to 1.48), UTI (RR 1.06, 95% CI 0.73 to 1.64), or sepsis (RR 0.79, 95% CI 0.50 to 1.26). CONCLUSIONS: Compared to clopidogrel, ticagrelor reduces the risk of pneumonia, but not URTI, UTI or sepsis. Our study provides further evidence for recommending ticagrelor to patients with acute coronary syndrome at risk of pneumonia, although the mechanism by which ticagrelor reduces the risk of pneumonia merits further research. SN - 2055-6845 UR - https://www.unboundmedicine.com/medline/citation/32569384/Risk_of_infections_in_patients_treated_with_ticagrelor_versus_clopidogrel:_a_systematic_review_and_meta-analysis L2 - https://academic.oup.com/ehjcvp/article-lookup/doi/10.1093/ehjcvp/pvaa065 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.